Immunotherapy plus chemo before surgery for advanced ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new immunotherapy drug (AK104) combined with chemotherapy before surgery for advanced ovarian cancer. The goal is to see if this combination shrinks tumors more effectively, helping more patients have successful surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have advanced ovarian, fallopian tube, or primary peritoneal cancer (certain types) that has spread (stage III or IV).
- Your doctor has recommended chemotherapy before surgery (neoadjuvant) because the tumor is too large or your health is too fragile for immediate surgery.
- You must have at least one tumor that can be measured on a scan.
- You cannot have had any prior cancer treatment for ovarian cancer, and you must not have active autoimmune diseases, serious infections, or other cancers in the past 5 years (except a few cured early-stage cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AK104 combined with standard chemotherapy and either cetuximab or bevacizumab for people with metastatic colorectal cancer that cannot be surgically removed. It is for those who have had only one prior line of treatment and whose tumors are not MSI-H or have a BRAF mutation.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy before surgery for advanced ovarian cancer. The goal is to see if this treatment shrinks the cancer more and makes surgery more effective.
This trial tests a new immunotherapy drug (PD-1/CTLA-4 bispecific) combined with two chemotherapy drugs (nab-paclitaxel and carboplatin) given before surgery for advanced ovarian cancer. The goal is to shrink the tumor enough so it can be completely removed during surgery.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tovorilimab) plus bevacizumab and chemotherapy before surgery for advanced ovarian cancer that cannot be removed surgically at first. The goal is to see if this treatment can shrink the tumor enough to allow surgery.
This trial tests a combination treatment for advanced ovarian cancer that hasn't been treated before. It combines chemotherapy, a personalized vaccine made from your own immune cells, and a drug called pembrolizumab to help your immune system fight the cancer.
This trial tests a new drug called AK112 combined with chemotherapy or another drug (olaparib) for people with ovarian cancer that came back more than 6 months after platinum treatment. The goal is to see if these combinations work better than current options.
Hear when a new Advanced Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.